







ORIGINAL ARTICLE

Signs and symptoms of COVID-19 in patients with multiple sclerosis

Irene Schiavetti¹  | Luca Carmisciano¹ | Marta Ponzano¹  | Cinzia Cordioli² |
Eleonora Cocco^{3,4} | Girolama Alessandra Marfia⁵ | Matilde Inglese^{6,7} |
Massimo Filippi^{8,9,10,11,12}  | Marta Radaelli¹³ | Roberto Bergamaschi¹⁴ |
Paolo Immovilli¹⁵ | Marco Capobianco¹⁶  | Nicola De Rossi² | Giampaolo Bricchetto¹⁷  |
Cinzia Scandellari¹⁸ | Paola Cavalla¹⁹ | Ilaria Pesci²⁰ | Paolo Confalonieri²¹ |
Paola Perini²² | Maria Trojano²³ | Roberta Lanzillo²⁴  | Gioacchino Tedeschi²⁵ |
Giancarlo Comi²⁶  | Mario Alberto Battaglia^{27,28} | Francesco Patti^{29,30}  |
Marco Salvetti^{31,32} | Maria Pia Sormani^{1,7} | MuSC-19 Study Group

¹Department of Health Sciences, University of Genova, Genoa, Italy

²Centro Sclerosi Multipla ASST Spedali Civili di Brescia, Montichiari, Italy

³Centro Sclerosi Multipla, ATS Sardegna, Cagliari, Italy

⁴Dipartimento Scienze Mediche e Sanità Pubblica, Università di Cagliari, Cagliari, Italy

⁵Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy

⁶Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy

⁷IRCCS Ospedale Policlinico San Martino, Genoa, Italy

⁸Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

⁹Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

¹⁰Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

¹¹Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

¹²Vita-Salute San Raffaele University, Milan, Italy

¹³Department of Neurology and Multiple Sclerosis Center, ASST 'Papa Giovanni XXIII', Bergamo, Italy

¹⁴Multiple Sclerosis Research Center, IRCCS Mondino Foundation, Pavia, Italy

¹⁵Multiple Sclerosis Center, Ospedale Guglielmo da Saliceto, Piacenza, Italy

¹⁶Regional Referral Multiple Sclerosis Centre, Department of Neurology, University Hospital San Luigi, Orbassano, Torino, Italy

¹⁷AIMS Rehabilitation Center, Italian MS Society, Genoa, Italy

¹⁸IRCCS Istituto delle Scienze Neurologiche di Bologna, UOSI Riabilitazione Sclerosi Multipla, Bologna, Italy

¹⁹MS Center, Department of Neuroscience, City of Health and Science University Hospital of Turin, Turin, Italy

²⁰Centro SM UOC Neurologia, Fidenza, AUSL PR, Fidenza, Italy

²¹Multiple Sclerosis Centre, Neuroimmunology Department 'Carlo Besta' Neurological Institute, Milan, Italy

²²Department of Neurology Multiple Sclerosis Center, University of Padua, Padova, Italy

²³Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy

²⁴Federico II University of Naples, Naples, Italy

²⁵Department of Advanced Medical and Surgical Sciences, University of Campania, Naples, Italy

²⁶Università Vita Salute San Raffaele, Casa di Cura Privata del Policlinico, Milan, Italy

²⁷Research Department, Italian Multiple Sclerosis Foundation, Genoa, Italy

²⁸Department of Life Sciences, University of Siena, Siena, Italy

²⁹Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, Catania, Italy

³⁰Centro Sclerosi Multipla, Policlinico Catania, University of Catania, Catania, Italy

MuSC-19 Study Group members are presented in Appendix S1.

³¹Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy

³²Unit of Neurology, IRCCS Neuromed, Pozzilli, Italy

Correspondence

Irene Schiavetti, Section of Biostatistics,
Department of Health Sciences,
University of Genoa, Genoa, Italy.
Email: irene.schiavetti@unige.it

Abstract

Background and purpose: Clinical outcomes of multiple sclerosis (MS) patients affected by coronavirus disease 2019 (COVID-19) have been thoroughly investigated, but a further analysis on main signs and symptoms and their risk factors still needs attention. The objective of this study was to group together and describe based on similarity the most common signs and symptoms of COVID-19 in MS patients and identify all factors associated with their manifestation.

Method: Logistic and linear regression models were run to recognize factors associated with each pooled group of symptoms and their total number.

Results: From March 2020 to November 2021, data were collected from 1354 MS patients with confirmed infection of COVID-19. Ageusia and anosmia was less frequent in older people (odds ratio [OR] 0.98; $p = 0.005$) and more in smoker patients (OR 1.39; $p = 0.049$). Smoke was also associated with an incremental number of symptoms (OR 1.24; $p = 0.031$), substance abuse (drugs or alcohol), conjunctivitis and rash (OR 5.20; $p = 0.042$) and the presence of at least one comorbidity with shortness of breath, tachycardia or chest pain (OR 1.24; $p = 0.008$). Some disease-modifying therapies were associated with greater frequencies of certain COVID-19 symptoms (association between anti-CD20 therapies and increment in the number of concomitant symptoms: OR 1.29; $p = 0.05$). Differences in frequencies between the three waves were found for flu-like symptoms (G1, $p = 0.024$), joint or muscle pain (G2, $p = 0.013$) and ageusia and anosmia (G5, $p < 0.001$). All cases should be referred to variants up to Delta.

Conclusion: Several factors along with the choice of specific therapeutic approaches might have a different impact on the occurrence of some COVID-19 symptoms.

KEYWORDS

COVID-19, demyelinating diseases, disease-modifying treatment, multiple sclerosis, neurological disorders

INTRODUCTION

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the coronavirus disease 2019 (COVID-19) pandemic, has an extremely variable course, with cases ranging from asymptomatic to mild, moderate, severe as well as critical or fatal [1].

Symptoms usually appear within the first 2 weeks after exposure to the virus and some are more likely to be associated with COVID-19 than others. The clinical manifestations of COVID-19 are mainly fever or chills, cough, anosmia and ageusia, and difficulty breathing, but a variety of other symptoms are also involved: sore throat, loss of appetite, extreme fatigue, tiredness, headache, body aches, nausea, vomiting and diarrhoea [2]. However, new and unusual signs and symptoms have been found in newly infected patients from the beginning of the pandemic to date, following continuing viral mutations [3].

The association between symptoms and disease severity has already been explored in the general population. A recent study on 531 patients analysed the difference in symptoms of the coronavirus disease amongst hospitalized and non-hospitalized patients: shortness of breath is more common in hospitalized patients than in those with mild forms of the disease, whereas fatigue, headache and myalgia are mostly reported by not hospitalized subjects [4].

For containing pandemic transmission, an early diagnosis is essential, by identifying sentinel symptoms so that infected persons can self-isolate themselves just before they get contagious and start spreading the virus [5]. However, due to their high non-specificity, neither the presence nor the absence of a single symptom can be considered indicative of COVID-19 disease [6]. Some particular COVID-19 symptoms are often related and tend to appear together, and therefore combined into specific groups may predict COVID-19 very accurately [7].

In Italy there are more than 120,000 people with multiple sclerosis (MS) [8], most of them treated with disease-modifying therapies which alter the components of the immune system and are associated with a greater infectious risk, especially viral [9]. In addition, the association between dysimmune phenomena underlying MS and the defective control of some pathogens has driven researchers around the world to focus on clinical outcomes in MS patients affected by COVID-19 [10–14]. However, a more in-depth analysis focusing on the major signs and symptoms and related risk factors for their occurrence still requires further examination. This is even more so since a wide comprehension of the main symptoms present during infection is essential for providing advice and for monitoring the severity of long-term symptoms [15].

The aim of this study was to identify and group for similarity the most common signs and symptoms of COVID-19 and evaluate all factors associated with their manifestation.

METHODS

All demographic and clinical information was extracted from a dedicated web-based platform set up for the Italian MuSC-19 project that collects clinically reported data regarding the impact of COVID-19 infection on people affected by MS. Missing data on baseline characteristics were replaced with a procedure of multiple imputation by the chained equations algorithm, as detailed elsewhere [10].

Patients with a detailed history of MS and a confirmed (by reverse transcription polymerase chain reaction or serological test) symptomatic COVID-19 infection were included in the sample. Descriptive data were presented as mean with standard deviation (SD), median with range or interquartile range (IQR) for continuous variables, and number with percentage for categorical variables, as appropriate.

Symptoms collected in the MuSC-19 registry were based on patient reports along with physical examination performed during the routine visit. All of them were referred as symptoms associated with COVID infection, so presenting during or soon after COVID, and therefore they are supposed not to be present before COVID. Symptoms were pooled as per similarity into categories as proposed in a previous work [16] and the degree of agreement between different groups of symptoms was measured by Cohen's kappa. A patient was positive for a symptom group if he/she had at least one of the symptoms listed in that group.

Univariate and subsequent logistic regression models were run to recognize all factors associated with each group of symptoms by controlling for baseline characteristics. In addition, univariate and the following multivariate linear regression models were applied to identify all predicting factors for an increase in the total number of symptom groups. Only variables which have previously resulted in a significant association with at least one group of symptoms were included in the model as independent factors.

Finally, an analysis of the distribution of symptom groups between three pandemic waves was performed for discussing any differences in their frequencies of comparison (chi-squared test).

The study was approved by the Regional Ethics Committee of Liguria (University of Genoa; no. 130/2020–DB id10433) and on a national level by Agenzia Italiana del Farmaco (AIFA).

RESULTS

From March 2020 to November 2021, data were collected from 2112 MS patients in care at 121 Italian sites. Of them 1354 had a confirmed infection of COVID-19, presented at least one sign or symptom of disease, and showed a completed follow-up until recovery (98.6%) or death (1.4%).

The mean age was 43.8 years (IQR 34.0–53.0), 67.3% were females and, of them, pregnancy was reported in 2%.

On average, patients lived with two cohabitants, without children (IQR 0.0–1.0), or with another COVID-19-positive cohabitant besides them (IQR 0.0–2.0). About lifestyle-related factors, 198 (14.6%) were current smokers, 260 (19.2%) were former smokers and 896 (66.2%) had never smoked. Alcohol was consumed by 56.0% of patients, with regular consumption in 2.0%. Abuse of substance, defined by the National Cancer Institute as 'the use of illegal drugs or the use of prescription or over-the-counter drugs or alcohol for purposes other than those for which they are meant to be used, or in excessive amounts' was reported by 25 patients (1.8%).

Patients had a median Expanded Disability Status Scale (EDSS) of 2 (IQR 1–3.5), and the proportion of progressive patients was 13.8%. In all, 1152 (85.1%) patients were treated with a disease-modifying therapy; recent use of methylprednisolone was declared for 84 patients (6.2%). About two-thirds of patients (72.1%) had no comorbidities.

COVID-19 severity was defined by three levels: 1152 (85.1%) patients with mild disease not requiring hospitalization, 173 (12.8%) cases of pneumonia and/or hospitalization, and 29 (2.1%) cases of admission in an intensive care unit and/or death (Table 1).

Reported symptoms were grouped as follows.

1. Group 1 (G1): Fever, chills, dyspnoea, cough, sputum production, lymph nodes enlarged, tonsil swelling, throat congestion, nasal congestion, sore throat, cold
2. Group 2 (G2): Arthralgia, myalgia, bone and joint pain, back pain
3. Group 3 (G3): Shortness of breath, tachycardia, chest pain
4. Group 4 (G4): Vomiting, nausea, diarrhoea, abdominal pain, loss of appetite, loss of weight, other gastrointestinal symptoms
5. Group 5 (G5): Ageusia, anosmia
6. Group 6 (G6): Symptoms of anxiety and depression, insomnia, headache, drowsiness, difficulty sleeping, loss of concentration, weakness, fatigue, asthenia
7. Group 7 (G7): Conjunctivitis, rash

TABLE 1 Baseline characteristics

Sex, females	911 (67.3%)
Age, mean \pm SD	43.8 \pm 12.29
Pregnancy (N = 911 females)	18 (2.0%)
Number of cohabitants, median (IQR)	2.0 (1.0–3.0)
Number of cohabitant children, median (IQR)	0.0 (0.0–1.0)
Number of COVID-positive cohabitants, median (IQR)	1.0 (0.0–2.0)
Smoking habits	
Never smoked	896 (66.2%)
Former smoker	260 (19.2%)
Current smoker	198 (14.6%)
Alcohol consumers	
No consumption	596 (44.0%)
Occasional consumption	731 (54.0%)
Regular consumption	27 (2.0%)
Substance abusers	25 (1.8%)
Presence of at least one comorbidity	378 (27.9%)
Progressive MS	187 (13.8%)
MS disease duration, mean \pm SD	10.4 \pm 8.28
Last EDSS, median (IQR)	2.0 (1.0–3.5)
Last DMT	
Dimethyl fumarate	256 (18.9%)
No therapy	202 (14.9%)
Anti-CD20	184 (13.6%)
Natalizumab	176 (13.0%)
Fingolimod	161 (11.9%)
Interferon	127 (9.4%)
Glatiramer acetate	97 (7.2%)
Teriflunomide	91 (6.7%)
Cladribine	24 (1.8%)
Other	36 (2.7%)
Recent use of methylprednisolone	84 (6.2%)
Previous vaccination against COVID-19	24 (1.8%)
COVID-19 severity	
Mild disease with no pneumonia nor requiring hospitalization	1152 (85.1%)
Pneumonia and/or hospitalization	173 (12.8%)
ICU and/or death	29 (2.1%)

Note: Results are expressed as mean \pm SD, median (IQR), count (%). Abbreviations: COVID-19, coronavirus disease 2019; DMT, Disease modifying treatment; EDSS, expanded disability status scale; ICU, intensive care unit; IQR, interquartile range; MS, multiple sclerosis.

The frequency of occurrence of single and grouped symptoms is reported in Figure 1, whereas Table 2 details their grade of agreement.

Patients declared nearly three groups of symptoms (mean 2.7, range 1–7). The most common was G1 in 1211 patients (89.4%), followed by G6 in 841 (62.1%) of the patients. None or slight agreement

(Cohen's kappa $<$ 0.20) for each pairwise comparison was found (except a fair agreement between G2 and G6), confirming their independence from each other.

Figure 2 reports results from multivariate models regarding factors associated with each group of symptoms and factors associated with an increased number of symptoms. Males showed a lower risk for developing joint or muscle pain (G2) and gastrointestinal symptoms (G4) and for having an increment in the total number of symptom groups (OR 0.86, 95% CI 0.74–0.99; $p = 0.037$).

Ageusia and anosmia (G5) were less frequently reported in older people (OR 0.98, 95% CI 0.97–0.99; $p = 0.005$) and more common in smoker patients (OR 1.39, 95% CI 1.00–1.94; $p = 0.049$). In addition, the smoking habit was demonstrated to be a risk factor for developing an increment in the total number of symptom groups (OR 1.24, 95% CI 1.02–1.51; $p = 0.031$). Substance abuse was associated with the occurrence of greater frequency of conjunctivitis and rash (G7; OR 5.20, 95% CI 1.06–25.54; $p = 0.042$), whereas the presence of at least one comorbidity was associated with shortness of breath, tachycardia or chest pain (G3; OR 1.24; 95% CI 1.06–1.45; $p = 0.008$).

An increasing MS disease duration and EDSS were significantly associated with lower occurrences of several symptoms (G2, G4, G5, G6). The use of some classes of MS therapies seems to be associated with the presence of some groups of symptoms; in particular the infusion of anti-CD20 therapies was found to be associated with an increment in the number of concomitant symptoms (OR 1.29, 95% CI 1.00–1.67; $p = 0.05$). Twenty-four patients (1.8%) were found to be previously immunized against COVID-19. There were no differences in the frequency of occurrence of any of the symptom groups studied between vaccinated and unvaccinated patients before infection (always $p > 0.10$, data not shown).

Figure 3 illustrates the distribution of the group of symptoms during the three pandemic waves. In all the waves the most frequent groups of signs and symptoms were fever and flu-like symptoms, although less common in the second wave (87.9%) compared to the first (93.4%) and third (92.6%; $p = 0.024$). Then, for all three waves, 'mental' symptoms (G6) were very common ($>$ 50% of patients), followed by ageusia and anosmia in the first wave (36.8%) and joint/muscle pain in the second (39.8%) and third waves (44.3%). In addition, differences in frequencies amongst the three waves were found for joint or muscle pain (G2, $p = 0.013$) and ageusia and anosmia (G5, $p < 0.001$; Table 3).

Finally, all cases should be referred to variants up to Delta. Indeed, Omicron was detected for the first time in Italy on 11 November 2021 and data were collected just from March 2020 to November 2021.

DISCUSSION

A recent review states that the most common symptoms were fever (68.8%), followed by cough (63.9%), fatigue/asthenia (51.2%) [17]. The present study reports in the same order fever and cough (89.4%)




FIGURE 1 Frequency of single symptoms and grouped symptoms

TABLE 2 Group of symptoms and their agreement degree

N (%)	Group	Cohen's kappa (p value)					
		G2	G3	G4	G5	G6	G7
1211 (89.4%)	G1	0.05 (<0.001)	0.03 (<0.001)	0.01 (0.32)	-0.09 (<0.001)	0.05 (0.007)	0.00 (0.21)
513 (37.9%)	G2	-	0.17 (<0.001)	0.13 (<0.001)	0.11 (<0.001)	0.27 (<0.001)	0.02 (0.12)
224 (16.5%)	G3	-	-	0.08 (0.003)	0.03 (0.13)	0.09 (<0.001)	0.03 (0.11)
188 (13.9%)	G4	-	-	-	0.04 (0.044)	0.06 (<0.001)	0.07 (<0.001)
621 (45.9%)	G5	-	-	-	-	0.06 (0.030)	0.00 (0.79)
841 (62.1%)	G6	-	-	-	-	-	0.01 (0.12)
29 (2.1%)	G7	-	-	-	-	-	-

Note: G1: Fever, chills, dyspnoea, cough, sputum production, lymph nodes enlarged, tonsil swelling, throat congestion, nasal congestion, sore throat, cold. G2: Arthralgia, myalgia, bone and joint pain, back pain. G3: Shortness of breath, tachycardia, chest pain. G4: Vomiting, nausea, diarrhoea, abdominal pain, loss of appetite, loss of weight, other gastrointestinal symptoms. G5: Ageusia, anosmia. G6: Symptoms of anxiety and depression, insomnia, headache, drowsiness, difficulty sleeping, loss of concentration, weakness, fatigue, asthenia. G7: Conjunctivitis, rash.

and fatigue and asthenia together with other 'neurological' symptoms (62.1%). However, other than fatigue (48.8%) and headache (34.0%), there are few central nervous system symptoms, even in MS.

Several associations between comparison of some group of symptoms and other characteristics have been detected. Males are less likely to develop some symptoms (i.e., bone and joint pain

	G1	G2	G3	G4	G5	G6	G7	TOT	
Males, sex	1.45 (0.99 - 2.20), 0.08	0.67 (0.52 - 0.87), 0.002	1.10 (0.80 - 1.52), 0.56	0.54 (0.37 - 0.79), 0.002	0.83 (0.64 - 1.06), 0.13	0.98 (0.76 - 1.25), 0.85	0.72 (0.30 - 1.74), 0.47	0.86 (0.74 - 0.99), 0.037	 Risk factor Protective factor
Age	1.01 (0.99 - 1.03), 0.40	1.01 (1.0 - 1.02), 0.07	1.02 (1.00 - 1.03), 0.05	1.00 (0.99 - 1.02), 0.68	0.98 (0.97 - 0.99), 0.005	1.00 (0.99 - 1.01), 0.95	0.99 (0.95 - 1.03), 0.60	1.00 (0.99 - 1.01), 0.71	
Former smoker	0.76 (0.48 - 1.22), 0.26	1.10 (0.81 - 1.49), 0.53	0.95 (0.64 - 1.42), 0.82	1.30 (0.87 - 1.95), 0.21	1.34 (0.99 - 1.81), 0.06	1.14 (0.84 - 1.54), 0.40	1.17 (0.44 - 3.12), 0.76	1.14 (0.96 - 1.36), 0.14	
Current smoker	0.94 (0.56 - 1.60), 0.83	1.36 (0.98 - 1.90), 0.07	1.41 (0.94 - 2.13), 0.10	1.05 (0.66 - 1.68), 0.83	1.33 (1.00 - 1.94), 0.049	1.04 (0.75 - 1.44), 0.83	1.10 (0.39 - 3.15), 0.86	1.24 (1.02 - 1.51), 0.031	
Alcohol	1.00 (0.69 - 1.46), 0.99	1.00 (0.79 - 1.28), 0.98	1.04 (0.76 - 1.43), 0.79	1.05 (0.75 - 1.46), 0.79	1.10 (0.87 - 1.40), 0.42	1.01 (0.80 - 1.28), 0.93	1.29 (0.57 - 2.91), 0.54		
Abuse	1.18 (0.26 - 5.24), 0.83	0.74 (0.31 - 1.78), 0.50	1.53 (0.58 - 4.00), 0.39	2.06 (0.74 - 5.74), 0.17	1.08 (0.47 - 2.48), 0.85	1.01 (0.43 - 2.33), 0.99	5.20 (1.06 - 25.54), 0.042	1.20 (0.73 - 1.99), 0.47	
Comorbidities	1.20 (0.89 - 1.63), 0.23	0.98 (0.84 - 1.14), 0.81	1.24 (1.06 - 1.45), 0.008	1.10 (0.91 - 1.33), 0.32	0.89 (0.76 - 1.05), 0.16	0.98 (0.85 - 1.13), 0.80	0.85 (0.43 - 1.66), 0.63	1.03 (0.94 - 1.12), 0.56	
Progressive MS	1.84 (0.76 - 4.47), 0.18	0.68 (0.42 - 1.10), 0.12	0.96 (0.55 - 1.66), 0.87	1.11 (0.55 - 2.22), 0.78	0.67 (0.41 - 1.09), 0.10	0.88 (0.56 - 1.40), 0.59	0.89 (0.18 - 4.33), 0.88	0.87 (0.66 - 1.14), 0.31	
MS disease duration	0.99 (0.97 - 1.02), 0.70	0.98 (0.97 - 1.00), 0.07	0.98 (0.96 - 1.00), 0.11	0.99 (0.97 - 1.01), 0.46	0.99 (0.98 - 1.01), 0.32	0.98 (0.97 - 1.00), 0.035	1.02 (0.97 - 1.08), 0.45	0.99 (0.98 - 1.00), 0.012	
EDSS	1.09 (0.95 - 1.26), 0.21	0.91 (0.84 - 1.00), 0.044	1.03 (0.92 - 1.14), 0.62	0.86 (0.75 - 0.97), 0.017	0.91 (0.83 - 0.99), 0.030	1.01 (0.92 - 1.09), 0.90	0.92 (0.65 - 1.24), 0.60	0.95 (0.91 - 1.00), 0.05	
Interferon	1.18 (0.60 - 2.35), 0.63	0.76 (0.46 - 1.23), 0.26	0.76 (0.41 - 1.39), 0.37	0.72 (0.36 - 1.44), 0.35	1.62 (1.01 - 2.63), 0.048	0.86 (0.54 - 1.38), 0.55	2.04 (0.33 - 12.83), 0.45	0.96 (0.72 - 1.28), 0.78	
Glitamer acetate	0.89 (0.44 - 1.82), 0.75	1.17 (0.70 - 1.96), 0.55	0.75 (0.39 - 1.44), 0.39	1.21 (0.61 - 2.41), 0.59	1.21 (0.72 - 2.04), 0.47	1.18 (0.70 - 2.00), 0.53	1.68 (0.22 - 12.66), 0.61	1.10 (0.80 - 1.50), 0.56	
Teriflunomide	2.39 (0.93 - 6.14), 0.07	0.80 (0.47 - 1.37), 0.41	0.41 (0.19 - 0.90), 0.026	1.17 (0.58 - 2.38), 0.66	0.59 (0.34 - 1.02), 0.06	0.69 (0.41 - 1.15), 0.15	1.97 (0.26 - 14.63), 0.51	0.76 (0.51 - 1.04), 0.09	
Dimethyl fumarate	2.88 (1.44 - 5.74), 0.003	1.13 (0.75 - 1.70), 0.57	0.78 (0.47 - 1.31), 0.36	0.69 (0.38 - 1.25), 0.22	1.22 (0.81 - 1.84), 0.35	0.92 (0.61 - 1.39), 0.69	0.88 (0.14 - 5.60), 0.89	1.07 (0.83 - 1.37), 0.61	
Natalizumab	1.12 (0.60 - 2.11), 0.72	0.71 (0.45 - 1.13), 0.15	0.48 (0.25 - 0.89), 0.021	0.82 (0.43 - 1.55), 0.53	1.04 (0.67 - 1.63), 0.85	0.83 (0.53 - 1.29), 0.40	1.82 (0.31 - 10.64), 0.51	0.81 (0.62 - 1.06), 0.13	
Fingolimod	1.50 (0.76 - 2.94), 0.24	0.73 (0.46 - 1.15), 0.18	0.50 (0.27 - 0.92), 0.026	1.39 (0.77 - 2.52), 0.28	0.76 (0.49 - 1.20), 0.24	0.95 (0.61 - 1.48), 0.83	1.59 (0.26 - 9.91), 0.62	0.86 (0.66 - 1.12), 0.27	
Anti-CD20	1.86 (0.90 - 3.84), 0.10	1.42 (0.93 - 2.19), 0.11	1.22 (0.75 - 2.01), 0.43	1.06 (0.57 - 1.97), 0.84	0.82 (0.53 - 1.27), 0.37	1.59 (1.02 - 2.46), 0.039	5.08 (1.05 - 24.51), 0.043	1.29 (1.00 - 1.67), 0.05	
Cladribine	2.14 (0.46 - 10.03), 0.33	2.24 (0.90 - 5.52), 0.08	1.37 (0.49 - 3.83), 0.55	2.03 (0.71 - 5.85), 0.19	1.20 (0.49 - 2.94), 0.69	0.93 (0.38 - 2.29), 0.88	3.19 (0.25 - 40.05), 0.37	1.59 (0.90 - 2.74), 0.09	
Other	0.56 (0.20 - 1.52), 0.25	0.81 (0.36 - 1.81), 0.60	0.66 (0.25 - 1.70), 0.39	0.85 (0.27 - 2.67), 0.79	1.63 (0.76 - 3.49), 0.21	1.74 (0.79 - 3.83), 0.17	0 (0 -), 0.99	1.03 (0.66 - 1.61), 0.91	
Methylprednisolone	1.00 (0.46 - 2.16), 0.99	1.53 (0.97 - 2.43), 0.07	0.77 (0.40 - 1.47), 0.43	0.51 (0.22 - 1.14), 0.10	0.77 (0.48 - 1.23), 0.27	1.17 (0.73 - 1.88), 0.52	1.70 (0.48 - 6.01), 0.41	0.99 (0.75 - 1.31), 0.95	

FIGURE 2 Heat map of correlation, as measured by odds ratio estimates, between factors and each symptom group. Values above 1 (shade of red) indicate risk factors, below 1 (shade of green) protective factors




FIGURE 3 Distribution of symptom groups over time, with identification of the three pandemic waves

Group of symptoms	First wave (N = 238)	Second wave (N = 782)	Third wave (N = 122)	p
G1	226 (93.4%)	687 (87.9%)	113 (92.6%)	0.024
G2	74 (30.6%)	311 (39.8%)	54 (44.3%)	0.013
G3	47 (19.4%)	115 (14.7%)	24 (19.7%)	0.12
G4	33 (13.6%)	102 (13.0%)	16 (13.1%)	0.97
G5	89 (36.8%)	392 (50.1%)	42 (34.4%)	<0.001
G6	137 (56.6%)	483 (61.8%)	81 (66.4%)	0.16
G7	7 (2.9%)	16 (2.0%)	2 (1.6%)	0.67

TABLE 3 Distribution of group of symptoms during the three pandemic waves

Note: As reported by the Ministry of Health (Andamento della mortalità giornaliera [SiSMG] nelle città italiane in relazione all'epidemia di COVID-19—1 Settembre 2020–16 Novembre 2021), first wave, 1 March–10 May 2020; second wave, 1 September 2020–9 January 2021; third wave, March 2021–May 2021. Bold values represent statistical significant results.

and gastrointestinal symptoms) and generally have a smaller set of symptoms than females. In a self-reported survey, females declared a significantly higher frequency of gastrointestinal symptoms during COVID-19 compared to men [18]. Even age influences the frequency of manifestation of some symptoms. In particular, the risk of developing anosmia decreased with increasing age [19]. However, this result could be explained because unawareness of olfactory dysfunction may increase with older age [20]. In contrast, as age increases, the probability of shortness of breath, tachycardia and chest pain increases. This symptomology is also much more common in subjects with pre-existing conditions [21].

The effect of substance abuse on eyes and skin, already observed in other studies not COVID-19 related, is noticeable [22, 23]. Smoking plays an important role in amplifying the cases of ageusia and anosmia, with an increasing trend from former to current smokers [24]. Also interesting is the effect (although not fully significant) on bone and joint pain and respiratory distress.

The impact of current smoking on COVID-19 progression is debated. Two systematic reviews published at the beginning of the pandemic described the relationship between smoking and COVID-19 suggesting the absence of association between active smoking and enhanced risk of progression of COVID-19 [25, 26]. Subsequent papers have illustrated the most methodological problems with these studies (i.e., lack of detailed assessments of dose and duration for smoking, missing data), and promoted a worse COVID-19 progression and outcomes in smokers compared to other persons [27, 28].

In the present study, smoking is shown to be a risk factor in increasing the number of multiple symptoms that occur during COVID-19. The association between lower EDSS and the presence of some symptoms is probably due to an already underlying presence of some common symptoms in most critical MS patients, which consequently for them were not reported.

Teriflunomide, natalizumab and fingolimod appear to have some sort of protective role in the development of shortness of breath, tachycardia and chest pain, whereas the role of anti-CD20 in increasing the likelihood of neurological disorders (G6) and the occurrence of conjunctivitis and rash (G7) as well as in determining increases in the total number of concomitant symptom groups is interesting. Dimethyl fumarate seems to increase flu or flu-like symptoms, a common effect already reported in other studies [29].

It was demonstrated that interferon-alpha interferes with the normal regenerative processes of the olfactory mucosa, causes depletion of oligominerals (such as zinc) involved in both taste and smell perception and exerts a neurotoxic action [30]. More serious cases of anosmia and ageusia in the present study have been found in patients treated with interferon. Similar cases of association between loss of the sense of smell and loss of the sense of taste associated with the use of interferon have been reported in the medical literature [31-33].

To date few studies have investigated and described clinical characteristics of COVID-19 patients by comparing the three waves [34, 35]. The period between the second and third wave does not correspond to a new increase in cases but rather to a long stagnation

[36]. A further analysis of symptom distribution amongst the three pandemic waves showed some differences. The cause for these variations is not yet identified, although different COVID-19 variants may explain it [37], even if Omicron seems to be detected for the first time after the follow-up period of this study. In addition, unfortunately, this study has not collected the molecular characterization of the COVID infection, and therefore it is not possible to know the strains of each infection. In addition, also the new treatments for patients introduced starting from the second wave may have played a role in symptom reshuffling [38].

Knowing possible risk factors, modifying some lifestyle behaviours and more accurately analysing the choice of certain therapeutic approaches might minimize the occurrence of COVID-19 symptoms.

CONFLICT OF INTEREST

Schiavetti I received consulting fees from Hippocrates Research, NovaNeuro, Sakura Italia, ADL Farmaceutici, Associazione Commissione Difesa Vista Onlus. Carmisciano L has nothing to disclose. Ponzano M has nothing to disclose. Inglese M received research grants from NIH, DOD, NMSS, FISM, and Teva Neuroscience; received fees for participating in advisory boards from Roche, Biogen, Merck and Genzyme. Radaelli M received speaker honoraria from Biogen Idec, Sanofi-Genzyme, Novartis and Merck Serono and funding for travel to scientific meetings from Biogen Idec, Sanofi-Genzyme, Novartis, Merck Serono, Teva and Roche. De Rossi N received speaker honoraria from Biogen Idec, Genzyme, Novartis, Sanofi-Aventis; received funding for participation in advisory board to Novartis, Biogen and Genzyme-Sanofi and for travel to scientific meetings from Biogen Idec, Teva, Sanofi-Genzyme, Roche, Almirall and Novartis. Immoilli P reports personal fees from Roche, personal fees from Biogen, personal fees from Merck, outside the submitted work. Capobianco M reports personal fees and non-financial support from Biogen, personal fees and non-financial support from Merck Serono, personal fees and non-financial support from Roche, personal fees and non-financial support from Novartis, personal fees and non-financial support from Sanofi, personal fees from Almirall, outside the submitted work. Confalonieri Phas received honoraria for speaking or consultation fees from Novartis and Biogen, has received funding for travel to attend scientific events or speaker honoraria from Merck Serono, Biogen Idec, Teva and Roche. He has also received institutional research support from Merck-Serono, Novartis and Roche. He is also principal investigator in clinical trials for Biogen, Merck Serono, Roche. Perini P has received honoraria for lectures and support for attending meetings and travel from Roche, Biogen, Merck, Novartis, Sanofi, Teva. Trojano M reports grants and personal fees from Biogen, grants and personal fees from Novartis, grants and personal fees from Roche, grants and personal fees from Merck, personal fees from Sanofi, personal fees from TEVA, from null, outside the submitted work. Comi G reports personal fees from Novartis, Teva Pharmaceutical Industries Ltd, Teva Italia Srl, Sanofi Genzyme, Genzyme Corporation, Genzyme Europe,

Merck KGaA, Merck Serono SpA, Celgene Group, Biogen Idec, Biogen Italia Srl, F. Hoffman-La Roche, Roche SpA, Almirall SpA, Forward Pharma, Medday, Excemed, outside the submitted work. Patti F reports grants from Biogen, grants from Merck, grants from FISM, grants from Onlus association, grants from University of Catania, personal fees from Almirall, personal fees from Bayer, personal fees from Biogen, personal fees from Merck, personal fees from Roche, personal fees from Sanofi, personal fees from TEVA, outside the submitted work. Salvetti M reports grants and personal fees from Biogen, grants and personal fees from Merck, grants and personal fees from Novartis, grants and personal fees from Roche, grants and personal fees from Sanofi, grants and personal fees from Teva, grants from Italian Multiple Sclerosis Foundation, grants from Sapienza University of Rome, outside the submitted work. Sormani MP reports grants from Roche, during the conduct of the study; personal fees from Biogen, Merck, Roche, Sanofi, Novartis, Medday, Geneuro, Celgene, Mylan outside the submitted work.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICS STATEMENT

The study was approved by the Regional Ethics Committee of Liguria (University of Genoa) (no. 130/2020—DB id10433) and at a national level by Agenzia Italiana del Farmaco (AIFA).

ORCID

Irene Schiavetti  <https://orcid.org/0000-0002-5460-2977>

Marta Ponzano  <https://orcid.org/0000-0003-4091-4686>

Massimo Filippi  <https://orcid.org/0000-0002-5485-0479>

Marco Capobianco  <https://orcid.org/0000-0003-2501-2932>

Giampaolo Brichetto  <https://orcid.org/0000-0003-2026-3572>

Roberta Lanzillo  <https://orcid.org/0000-0001-6388-8180>

Giancarlo Comi  <https://orcid.org/0000-0002-6989-1054>

Francesco Patti  <https://orcid.org/0000-0002-6923-0846>

REFERENCES

- Vena A, Giacobbe DR, Di Biagio A, et al. Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. *Clin Microbiol Infect.* 2020;26(11):1537-1544. doi:10.1016/j.cmi.2020.07.049
- Centers for Disease Control and Prevention. *Symptoms of COVID-19.* Centers for Disease Control and Prevention; 2021.
- Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). *StatPearls.* StatPearls Publishing; 2021.
- Pettrone K, Burnett E, Link-Gelles R, et al. Characteristics and risk factors of hospitalized and nonhospitalized COVID-19 patients, Atlanta, Georgia, USA, March–April 2020. *Emerg Infect Dis.* 2021;27(4):1164-1168. doi:10.3201/eid2704.204709
- Najafloo R, Majidi J, Asghari A, et al. Mechanism of anosmia caused by symptoms of COVID-19 and emerging treatments. *ACS Chem Neurosci.* 2021;12(20):3795-3805. doi:10.1021/acscchemneuro.1c00477
- Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. *Cochrane Database Syst Rev.* 2020;7(7):CD013665. doi:10.1002/14651858.CD013665
- Elliott J, Whitaker M, Bodinier B, et al. Predictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million people. *PLoS Med.* 2021;18(9):e1003777. doi:10.1371/journal.pmed.1003777
- Barometro della Sclerosi Multipla 2021. © AISM. ISBN 978-88-7148-152-4
- Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease modifying therapies and infectious risks in multiple sclerosis. *Nat Rev Neurol.* 2016;12:217-233.
- Sormani MP, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. *Ann Neurol.* 2021;89(4):780-789. doi:10.1002/ana.26028
- Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. *JAMA Neurol.* 2020;77(9):1079-1088. doi:10.1001/jamaneurol.2020.2581
- Fragoso YD, Schiavetti I, Carmisciano L, et al. Coronavirus disease 2019 in Latin American patients with multiple sclerosis. *Mult Scler Relat Disord.* 2021;55:103173. doi:10.1016/j.msard.2021.103173
- Landtblom AM, Berntsson SG, Boström I, Iacobaeus E. Multiple sclerosis and COVID-19: the Swedish experience. *Acta Neurol Scand.* 2021;144(3):229-235. doi:10.1111/ane.13453
- Sen S, Karabudak R, Schiavetti I, et al. The outcome of a national MS-COVID-19 study: what the Turkish MS cohort reveals? *Mult Scler Relat Disord.* 2021;52:102968. doi:10.1016/j.msard.2021.102968
- Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med.* 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z
- Kratzer B, Trapin D, Ettl P, et al. Immunological imprint of COVID-19 on human peripheral blood leukocyte populations. *Allergy.* 2021;76:751-765. doi:10.1111/all.14647
- Barzegar M, Mirmosayyeb O, Gajarzadeh M, et al. COVID-19 among patients with multiple sclerosis: a systematic review. *Neurol Neuroimmunol Neuroinflamm.* 2021;8(4):e1001. doi:10.1212/NXI.0000000000001001 [published correction appears in *Neurol Neuroimmunol Neuroinflamm.* 2021;8(5):e1050].
- Sierpiński R, Pinkas J, Jankowski M, et al. Sex differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders in 1942 nonhospitalized patients with coronavirus disease 2019 (COVID-19). *Pol Arch Intern Med.* 2020;130:501-505. doi:10.20452/pamw.15414
- Sehanobish E, Barbi M, Fong V, et al. COVID-19-induced anosmia and ageusia are associated with younger age and lower blood eosinophil counts. *Am J Rhinol Allergy.* 2021;35(6):830-839. doi:10.1177/19458924211004800
- Wehling E, Nordin S, Espeseth T, Reinvang I, Lundervold AJ. Unawareness of olfactory dysfunction and its association with cognitive functioning in middle aged and old adults. *Arch Clin Neuropsychol.* 2011;26(3):260-269. doi:10.1093/arclin/acr019
- Study ZOE COVID. Is shortness of breath a symptom of COVID-19?. Accessed April 1, 2021. <https://covid.joinzoe.com/post/covid-symptoms-shortness-breath>
- Jain NP, Shao K, Stewart C, Grant-Kels JM. The effects of alcohol and illicit drug use on the skin. *Clin Dermatol.* 2021;39(5):772-783. doi:10.1016/j.clindermatol.2021.05.005
- Gohil H, Miskovic M, Buxton JA, Holland SP, Strike C. Smoke gets in the eye: a systematic review of case reports of ocular complications of crack cocaine use. *Drug Alcohol Rev.* 2021;41(2):347-355. doi:10.1111/dar.13366
- Katotomichelakis M, Balatsouras D, Tripsianis G, et al. The effect of smoking on the olfactory function. *Rhinology.* 2007;45(4):273-280.

25. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). *Eur J Intern Med*. 2020;75:107-108. doi:10.1016/j.ejim.2020.03.014
26. Farsalinos K, Barbouni A, Poulas K, Polosa R, Caponnetto P, Niaura R. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. *Ther Adv Chronic Dis*. 2020;11:204062232093576. doi:10.1177/2040622320935765
27. van Westen-Lagerweij NA, Meijer E, Meeuwssen EG, et al. Are smokers protected against SARS-CoV-2 infection (COVID-19)? The origins of the myth. *NPJ Prim Care Respir Med*. 2021;31:10. doi:10.1038/s41533-021-00223-1
28. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. *J Med Virol*. 2020;92:1915-1921.
29. Fernández Ó, Giovannoni G, Fox RJ, et al. Efficacy and safety of delayed-release dimethyl fumarate for relapsing–remitting multiple sclerosis in prior interferon users: an integrated analysis of DEFINE and CONFIRM. *Clin Ther*. 2017;39(8):1671-1679. doi:10.1016/j.clinthera.2017.06.012
30. Equils O, Lekaj K, Wu A, Fattani S, Liu G, Rink L. Intra-nasal zinc level relationship to COVID-19 anosmia and type 1 interferon response: a proposal. *Laryngoscope Investig Otolaryngol*. 2020;6(1):21-24. doi:10.1002/lio2.513
31. Mayet AY. Loss of smell (anosmia) and taste (ageusia) in a patient treated with pegylated interferon alfa and ribavirin. *Curr Ther Res Clin Exp*. 2007;68(4):271-277. doi:10.1016/j.curtheres.2007.08.006
32. Kraus I, Vitezic D. Anosmia induced with alpha interferon in a patient with chronic hepatitis C. *Int J Clin Pharmacol Ther*. 2000;38(7):360-361. doi:10.5414/cpp38360
33. Maruyama S, Hirayama C, Kadowaki Y, Sagayama A, Omura H, Nakamoto M. Interferon-induced anosmia in a patient with chronic hepatitis C. *Am J Gastroenterol*. 1998;93:122-123.
34. Taboada M, González M, Alvarez A, et al. First, second and third wave of COVID-19. What have we changed in the ICU management of these patients? *J Infect*. 2021;82(6):e14-e15. doi:10.1016/j.jinf.2021.03.027
35. Borghesi A, Golemi S, Carapella N, Zigliani A, Farina D, Maroldi R. Lombardy, northern Italy: COVID-19 second wave less severe and deadly than the first? A preliminary investigation. *Infect Dis (Lond)*. 2021;53(5):370-375. doi:10.1080/23744235.2021.1884745
36. Jung C, Excoffier JB, Raphaël-Rousseau M, Salaün-Penquer N, Ortala M, Chouaid C. Evolution of hospitalized patient characteristics through the first three COVID-19 waves in Paris area using machine learning analysis. *PLoS One*. 2022;17(2):e0263266. doi:10.1371/journal.pone.0263266
37. Hodcroft EB, Zuber M, Nadeau S, et al. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. *Nature*. 2021;595(7869):707-712. doi:10.1038/s41586-021-03677-y
38. Lam S, Lombardi A, Ouanounou A. COVID-19: a review of the proposed pharmacological treatments. *Eur J Pharmacol*. 2020;886:173451. doi:10.1016/j.ejphar.2020.173451

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Schiavetti I, Carmisciano L, Ponzano M, et al. Signs and symptoms of COVID-19 in patients with multiple sclerosis. *Eur J Neurol*. 2022;00:1-9. doi: [10.1111/ene.15554](https://doi.org/10.1111/ene.15554)

MANAGE-PD

Tool for Making Informed Decisions to
Aid Timely Management of Parkinson's Disease



MANAGE-PD allows you to:

- Identify PD patients inadequately controlled on oral medications
- Determine which patients with PD may be adequately controlled on their current treatment regimen or may require changes to their treatment regimen



Scan the QR code to
access to the web

Click here to
access to the web



MANAGE-PD is an AbbVie Inc. registered Medical Device. It is a collaborative research and development effort between AbbVie Medical Affairs and Health Economics and Outcomes, the Parkinson's Foundation and an international panel of Movement Disorder Specialists.

©2022 AbbVie Inc. All rights reserved. The Parkinson's Foundation logo is the sole property of the Parkinson's Foundation used with written permission. Any use of the Parkinson's Foundation name or logo without Foundation permission is prohibited. All content in <https://www.managepd.eu/> is intended only for informational use by healthcare professionals and is not offered as or intended to be medical advice for any particular patient. This information is not intended for patients. Only a healthcare professional exercising independent clinical judgement can make decisions regarding appropriate patient care and treatment options considering the unique characteristics of each patient.

PD: Parkinson's Disease